Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

G-protein Coupled Receptors01:21

G-protein Coupled Receptors

125.0K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
125.0K
Depression: Overview01:18

Depression: Overview

460
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
460
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

457
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
457
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

14.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
14.1K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

913
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
913
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

1.2K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The emergence of chronic diseases of adulthood and middle age in the young: the COIDS (chronic inflammation, obesity, insulin resistance/type 2 diabetes, and depressive syndromes) noxious quartet of pro-inflammatory stress outcomes.

Molecular psychiatry·2025
Same author

Advances in discerning the mechanisms underlying depression and resiliency: relation to the neurobiology of stress and the effects of antidepressants.

Molecular psychiatry·2025
Same author

The neuroendocrinology of stress and the importance of a proper balance between the mineralocorticoid and glucocorticoid receptors.

Molecular psychiatry·2024
Same author

Comment on: Antidepressants act by directly binding to TRKB neurotrophin receptors.

Molecular psychiatry·2024
Same author

Re-assessing the catecholamine hypothesis of depression: the case of melancholic depression.

Molecular psychiatry·2021
Same author

Endocrine Factors in Key Structural and Intracellular Changes in Depression.

Trends in endocrinology and metabolism: TEM·2021

Related Experiment Video

Updated: Oct 20, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

275

The PPARg System in Major Depression: Pathophysiologic and Therapeutic Implications.

Philip W Gold1

  • 1National Institutes of Health, Bethesda, MD 20892, USA.

International Journal of Molecular Sciences
|September 10, 2021
PubMed
Summary

The PPARg system rapidly senses cellular stress and offers neuroprotection in depression by increasing brain-derived neurotrophic factor (BDNF) and improving neuroplasticity. PPARg agonists may offer significant antidepressant effects by targeting inflammation and insulin resistance.

Keywords:
PPARgamygdalacorticotropin releasing hormonedepressioninflammationneuropathologynorepinephrinenucleus accumbenssubgenual prefrontal cortex

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

677
Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

7.6K

Related Experiment Videos

Last Updated: Oct 20, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

275
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

677
Animal Models of Depression - Chronic Despair Model CDM
05:47

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

7.6K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Psychiatry

Background:

  • Depression is linked to neurodegeneration, reduced neuroplasticity, and impaired neurogenesis in key brain areas.
  • Brain-derived neurotrophic factor (BDNF) depletion is implicated in the neurodegeneration observed in depression.
  • Patients with depression often exhibit insulin resistance and systemic inflammation.

Purpose of the Study:

  • To investigate the role of the PPARg system in cellular stress response within the central nervous system.
  • To explore the potential of PPARg agonists in ameliorating depression-related neurobiological and physiological deficits.
  • To determine if PPARg augmentation can positively impact pathological processes associated with depressive illness.

Main Methods:

  • The study reviews existing literature on the PPARg system's function in glial cells, neurons, and cerebrovascular endothelial cells.
  • Analysis of the relationship between PPARg activity, BDNF levels, neuroplasticity, and neurogenesis.
  • Examination of PPARg's influence on inflammation, insulin resistance, and depressive symptoms.

Main Results:

  • The PPARg system demonstrates potent anti-inflammatory and neuroprotective functions in the CNS.
  • PPARg activation significantly increases BDNF levels and promotes neuroplasticity and neurogenesis.
  • PPARg agonists show potential in ameliorating inflammation and insulin resistance, key factors in depression's somatic manifestations.

Conclusions:

  • PPARg augmentation can positively influence multiple pathological processes in depression, including neurodegeneration, inflammation, and insulin resistance.
  • The PPARg system's multifaceted actions suggest its potential as a therapeutic target for depression.
  • PPARg agonists may offer significant antidepressant effects by addressing core biological dysfunctions in depressive illness.